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Abstract
OBJECTIVE: Our goal was to evaluate the analytical performance of the novel immunoassay platform and 
to compare the agreement between thyroid-stimulating hormone (TSH) and FT4 results, obtained by novel and 
currently used platform.
MATERIALS AND METHODS: Both immunoassay platforms, current Immulite 2000 and novel Maglumi 800, are 
based on chemiluminecsence immunoassay method. Analytical performance was evaluated by the use of serum 
pools and commercial quality control samples. The comparison study was carried out with 80 serum samples. 
Obtained results were analyzed by descriptive statistics, Mann–Whitney U-test, and Paired t-test. Method comparison 
was performed with Passing-Bablok regression analysis and Bland-Altman plots.
RESULTS: TSH Maglumi 800 showed better within-run precision for both concentration ranges (1.7–2.8 CV%) in 
comparison to Immulite 2000 (4.4–5.7 CV%). FT4 Maglumi 800 imprecision was higher compared with Immulite 
2000 FT4 in both within-run (3.5–3.9 CV% vs. 4.9–6.6 CV%) and between-run (3.6–4.2 CV% vs. 4.6–5.9 CV%) 
tests. Mann–Whitney U-test for TSH revealed non-significant difference between data (p = 0.9011). Regression 
analysis showed no systematic (intercept = 0.01), nor proportional (slope = 0.9781) differences. Non-significant 
bias was observed in Bland-Altman Plots. For FT4, we found significant differences between methods using paired 
t-test (t39 = 10.5, p < 0.0001) and significant difference (p = 0.00745) with Mann–Whitney U-test. Bland-Altman plot 
revealed 22.8% average bias.
CONCLUSION: TSH evaluation showed good precision and close agreement between Maglumi 800 and Immulite 
2000 methods, which assures transferability of results. However, FT4 performance evaluation revealed higher 
imprecision of Maglumi 800 platform and significant differences of test results.
Introduction
Thyroid function tests (TFTs) are important 
tool in diagnosis and monitoring of thyroid disorders. 
The assay menu includes thyroid hormones – thyroxine 
(T4) and triiodothyronine (T3), thyroglobulin, thyroid 
antibodies, and thyroid-stimulating hormone (TSH) 
from the pituitary. Serum TSH is the most important 
single measurement that can detect both overt and 
subclinical thyroid disorders [1]. The secretion is 
regulated by negative feedback mechanism from the 
free fraction of serum T4 (FT4) and free T3 (FT3). 
Even minor, non-pathological changes in FT4 and 
FT3 serum concentrations could influence TSH 
secretion, which confirms it as a sensitive biomarker 
for subclinical thyroid disorders [2]. Furthermore, TSH 
is useful in managing hormone replacement therapy 
in hypothyroidism and suppressive therapy in follicular 
cell thyroid cancer [3]. In regard with thyroid hormones 
assessment, FT4 has nowadays replaced total T4 
measurement, which is highly influenced by the amount 
of serum carrier proteins. Therefore, the majority of 
clinical chemistry laboratories perform TSH and FT4 as 
first-line TFTs [4], [5], [6] as demanded by clinicians.
Immunoassays have been dominant analytical 
techniques for these tests for several decades, starting 
with radioimmunoassay and improving the sensitivity 
and specificity by introducing new labels and techniques 
over time. Despite of automation of assay platforms, 
the test results exhibit substantial bias performed with 
reagents from different manufacturers and on different 
analyzers [7], [8], [9]. They implement various types 
of labels and antibodies, different standard reference 
material, as well as diversity of fraction separation 
techniques. Thus, a change of immunoassay platform 
and reagent manufacturer requires performance of 
a certain evaluation process to assess comparability 
between methods. The basic evaluation procedures are 
imprecision (within-run and between-run) assessment 
and method agreement testing.
The purpose of our study was to compare the 
agreement of the results for TSH and FT4 obtained with 
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different immunoassays, performed on novel Maglumi 
800 and the current Immulite 2000 automated analyzers. 
Close agreement would ensure the transferability 
of test results between platforms and their reporting 
within the previously established reference intervals for 
both analytes. Evaluation of analytical performance of 
TSH and FT4 immunoassays measured on Maglumi 
800 automated platform would reveal the extent of 
imprecision and reliability of test results.
Materials and Methods
Serum samples
The samples used for comparison study were 
80 sera of anonymous patients admitted for thyroid 
function examination at the Institute of Pathophysiology 
and Nuclear Medicine, Faculty of Medicine in Skopje. 
The samples were collected in evacuated tubes with 
cloth activator (CDRICH, China) and after serum 
separation, hemolytic, icteric, and lipemic samples were 
excluded from the study. After the initial assessment 
of TSH and FT4 from primary tubes with the routine 
immunoassay, tubes with results reflecting euthyroid, 
and hypothyroid and hyperthyroid status were selected 
for further analysis on the novel immunoassay platform. 
Collection of the samples was performed within 
2 weeks, and finally two groups of 40 samples [10] were 
obtained for the comparison study: One group for TSH 
and the other for FT4.
Quality control material
For within-run imprecision assessment of the 
novel method, we prepared two concentration levels 
of in-house pooled, quality control serum samples for 
each measurand. Ten replicate measurements were 
performed in one run for each concentration level. 
Between-run imprecision for median concentration 
level was assessed using commercial quality control 
sample, provided by the manufacturer (Snibe, China). 
For pathological, high concentration level, we used 
commercial Lyphochek Immunoassay Plus Control (Bio-
Rad, USA). The data were obtained for 10 consecutive 
days. Both of the imprecision data are expressed as 
coefficient of variation (CV %). The with-in and between-
run imprecision assessment for the routine method was 
performed using two concentration levels of Lyphochek 
Immunoassay Plus Control.
Methods
Both of the automated immunoassay analyzers 
– Immulite 2000 (Siemens Healthineers, USA) and 
Maglumi 800 (Snibe Co. Ltd., China) are based on 
CLIA methods. However, they differ in labeling and 
separation technology. Brief description of analyzers 
methodology and immunoassay tests, principles are 
presented below.
Immulite 2000 platform utilizes enzyme (alkaline 
phosphatase) labeled reagent, which reacts with the 
analyte from the serum sample in the test unit tube. 
The immune complex is captured on antibody coated 
bead placed in the test unit tube. After washing and 
centrifugation step, luminogenic substrate (adamantyl 
dioxetane phosphate) is added to the labeled immune 
complex, producing unstable intermediate dioxetane, 
which stabilizes by light emission, measured by the 
instrument in relative light units (RLU).
Immulite 2000 TSH is the third generation solid 
phase, two-site chemiluminescent immunometric assay, 
performed in a single incubation cycle. TSH from the sera 
is sandwiched between the capture monoclonal murine 
anti-TSH antibody, coated on the bead surface and 
polyclonal goat anti-TSH antibody, labeled with alkaline 
phosphatase. The signal, generated after substrate 
addition to the immune complex, is proportional to the 
serum TSH concentration. The assay calibrators are 
traceable to the WHO second International Reference 
Preparation 80/558.
Immulite 2000, FT4 is solid phase, competitive 
immunoassay. Patient serum is incubated in the test 
tube with a bead coated with monoclonal murine 
anti-T4 antibody and alkaline phosphatase conjugated 
to T4. Unbound fractions are removed from the tube 
with centrifuge washes and luminogenic substrate is 
added to immune complex to generate a light signal, 
inversely proportional to the concentration of free T4.
Maglumi 800 platform applies non-enzyme 
ABEI labeled reagents. ABEI (N-(4-aminobutyl)-N-
ethylisoluminol) is a small molecule which produces 
a flash of light in the presence of signaling reagents 
(NaOH and H2O2). The separation of labeled immune 
complex is performed by coated magnetic microbeads 
in magnetic field and unbound fraction is aspirated from 
the reaction micro wells.
Maglumi TSH is solid phase, two-site 
immunometric assay, performed using two different 
monoclonal anti-TSH antibodies. Serum TSH, ABEI 
labeled mouse anti-TSH monoclonal antibody, and 
magnetic microbeads coated with monoclonal anti-TSH 
antibody, are incubated in a single cycle. Subsequently, 
the sandwich immune complex is precipitated in 
magnetic field, afterward the signaling reagents is added 
to produce light, proportional to the TSH concentration. 
The assay calibrators are traceable to the WHO third 
International Reference Preparation 81/565.
Maglumi 800 FT4 is solid phase competitive 
immunoassay. The reaction occurs in micro wells after 
addition of serum, ABEI labeled anti-T4 monoclonal 
antibody and T4 antigen coated magnetic microbeads. 
After formation of immune-complex with the labeled 
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antibody and precipitation in magnetic field, the 
unbound liquid fractions are aspirated. The signaling 
reagents are introduced into the well, thus initiating a 
light that is detected as RLU, inversely proportional to 
the FT4 serum concentration.
Statistical analysis
TSH and FT4 within-run and between-run 
imprecision were analyzed by descriptive statistics 
(mean, standard deviation and CV %) using Microsoft 
Excel 2007. The significance of differences between 
paired groups was assessed with Mann–Whitney 
U-test and Paired t-test. Method comparison 
was performed using Passing-Bablok regression 
analysis [11] and Bland-Altman plots [12]. Passing-
Bablok defined regression equitation, including 
95% confidence intervals (CIs) and proportional 
and constant errors were calculated. For the TSH 
analysis, the results were log–transformed. For 
method comparison analysis, statistical package 
MedCalc v.14 was used.
Results
The data from the imprecision tests for each 
measurand are displayed on the tables. Different control 
materials were used for both tests and measurands, as 
mentioned previously. Nevertheless, the concentration 
ranges were selected to be comparable between 
analyzers. The results from the within-run test are 
expressed as mean values out of 10 replicates, and the 
imprecision as coefficient of variation.
Table 1: Within-run imprecision evaluation for TSH
Analyzer QC1 QC2
Mean±SD within-run Mean±SD within-run
mIE/L  CV% mIE/L CV%
Maglumi 800 0.481±0.008  1.7 3.392±0.09 2.8
Immulite 2000 0.573±0.025  4.4 5.084±0.29 5.7
QC: Quality control sample; 1Low range pooled control serum; 2Upper range pooled control serum; 3Low 
range Lyphochek control (Bio-Rad); 4Upper range Lyphochek control (Bio-Rad). SD: Standard deviation.
From the data presented on Table 1, it is 
evident that TSH performed on Maglumi 800 showed 
better within-run precision in both, normal and high 
concentration ranges (1.7–2.8 CV%) in comparison to 
Immulite 2000 (4.4–5.7 CV%). Between-run imprecision, 
tested during 10 consecutive days, showed better 
results for the high pathological control performed on 
Maglumi 800, but for the borderline upper range level, 
Immulite 2000 TSH was more precise (5.0 CV% vs. 5.9 
CV%) (Table 2).
Table 2: Between-run imprecision evaluation for TSH
Analyzer QC1 QC2
Mean±SD between-run Mean±SD between-run
mIE/L  CV% mIE/L  CV%
Maglumi 800 3.331±0.193  5.9 37.53±0.819  2.1
Immulite 2000 5.02±0.25  5.0 31.33±2.27  7.2
1Upper range snibe control; 2Upper range Lyphochek control (Bio-Rad); 3Pathological high Lyphochek 
control (Bio-Rad). SD: Standard deviation.
The results for FT4 imprecision evaluation, 
depicted on Tables 3 and 4, suggest higher precision 
obtained with Immulite 2000 FT4 in both within-run and 
between-run testing.
Table 3: Within-run imprecision evaluation for FT4
Analyzer QC1 QC2
Mean±SD within-run Mean±SD within-run
pmol/L  CV% pmol/L CV%
Maglumi 800 13.71±0.67  4.9 31.42±2.08 6.6
Immulite 2000 11.63±0.42  3.5 34.34±1.35 3.9
QC: Quality control sample; 1Low range pooled control serum; 2High range pooled control serum; 3Low 
range Lyphochek control (Bio-Rad); 4High range Lyphochek control (Bio-Rad). SD: Standard deviation.
In regard to method comparison, the first 
data were obtained using non-parametric Mann–
Whitney U-test. For TSH group, the results revealed 
non-significant difference between means of data 
(p = 0.9011), while for FT4 group the difference was 
significant (p = 0.00745). 
Table 4: Between-run imprecision evaluation for FT4
Analyzer QC1 QC2
Mean±SD between-run Mean±SD between-run
pmol/L CV% pmol/L  CV%
Maglumi 800 15.272±0.89 5.86 32.01±2.15  6.4
Immulite 2000 16.32±0.59 3.6 34.13±1.45  4.2
QC: Quality control sample; 1High range snibe control; 2Normal range Lyphochek control (Bio-Rad); 3High 
range Lyphochek control (Bio-Rad). SD: Standard deviation.
According to the paired t-test, we again did not 
found significant average differences between log-
transformed TSH values obtained by two analyzers 
(t39= ‒0.85, p = 0.39), as depicted on Figure 1.
Figure 1: Paired t-test for thyroid-stimulating hormone (TSH) Immulite 
2000 and TSH Maglumi 800 measurements
Passing-Bablok regression analysis for TSH 
group showed no systematic (intercept = 0.01, 95% 
CI = ‒0.0059–0.0196) nor proportional (slope = 0.9781, 
95% CI = 0.9367–1.0100) differences. The regression 
equitation and regression line are presented on 
Figure 2.
The agreement between two TSH methods 
was evaluated by Bland-Altman plots, with differences 
expressed as absolute units and percentage. The bias 
was estimated using limits of agreement. As depicted in 
Figure 3, the limits of agreement were narrow and the 
mean was close to the line of equality, which suggests 
good agreement between TSH Immulite 2000 and TSH 
Maglumi 800 results.
Analyzing FT4 results, we found significant 
average differences between methods, obtained by 
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Figure 2: Passing-Bablok regression line between thyroid-stimulating 
hormone (TSH) Immulite 2000 and TSH Maglumi 800 measurements
paired t-test (t39= 10.5, p < 0.0001), as displayed on 
Figure 4. Passing-Bablok regression analysis did 
not reveal significant systematic nor proportional 
differences.
Figure 3: Bland-Altman plots for thyroid stimulating hormone 
measurements: (a) Differences between Immulite 2000 and Maglumi 
800 measurements expressed as absolute units; (b) differences 
between Immulite 2000 and Maglumi 800 measurements expressed 
as percentage of values)
a
b
Regression equitation was y=0.527812+1.234375x, 
intercept value included zero (0.528, 95% CI 
from -2.4464–3.1568), and slope included one (1.2344, 
95% CI from 1.0943 to 1.4013). Regression line is 
presented in Figure 5.
Figure 4: Paired t-test for FT4 Immulite 2000 and FT4 Maglumi 800 
measurements
However, when we tested method agreement 
using Bland-Altman plot, we found overt bias of ‒4.7 
pmol/L and wide limits of agreement, expressed as 
absolute units (Figure 6a). 
Figure 5: Passing-Bablok regression line between FT4 Immulite 2000 
and FT4 Maglumi 800 measurements
Calculated as average percentage, the value obtained 
was below the line of equality, as well (Figure 6b). 
These foundings suggest that FT4 results performed 
on Maglumi 800 are higher in comparison to those 
performed on Immulite 2000, respectively.
Discussion
Initial evaluation of thyroid function can be 
performed by single TSH assessment and if TSH is out 
of reference range, with additional FT4 testing. This 
two-step approach has been recommended by different 
thyroid guidelines [13], [14]. However, in usual clinical 
practice, one-step assessment which includes both 
measurands simultaneously is often preferred [15]. 
This approach is generally practiced at IPMN as well. 
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Therefore, while introducing the new immunoassay test 
platform, we performed basic analytical performance 
evaluation and method comparison analysis for TSH 
and FT4 assays.
Initially, we verified the imprecision of both 
immunoassays and compared the results. TSH Maglumi 
800 assay performed by our laboratory showed 
excellent within-run precision (1.7–2.8 CV%) compared 
to manufacturer’s data for the similar concentration 
range (1.76–3.07 CV%). The between-run precision 
was lower compared to snibe results (2.1–5.9 CV% vs. 
1.4–2.04 CV%), but within the desirable imprecision 
limit of 9.7 CV%, as declared by Westgard for this 
measurand [16]. It is noteworthy that both reagent 
manufacturers use the extensive CLSI EP5-A2 
protocol [17] for the imprecision testing, including 80 test 
samples. For TSH Immulite 2000 assay, we obtained 
similar within-run imprecision with the manufacturer 
(4.4–5.7 CV% vs. 3.8–5.3 CV%), and 5–7.2 CV% for 
the between-run imprecision, a data which were not 
presented by manufacturer. Imprecision verification of 
both TSH assays performed in our laboratory showed 
better within-run precision for TSH Maglumi 800 assay.
For FT4 Maglumi 800 assay, our imprecision 
performance results were higher compared to 
manufacturer’s for both within and between-run (4.9–6.6 
CV% and 5.8–6.4 CV% respectively vs. 2.7–4.99 CV% 
and 1.51–6.17 CV%). The imprecision was higher when 
compared to FT4 Immulite 2000 assay as well. Our 
FT4 Immulite 2000 imprecision results were as follows: 
3.5–3.9 CV% for within and 3.6–4.2 CV% for between-
run imprecision, which were in agreement with data 
from manufacturer (3.0–7.8 CV%). However, if we apply 
the strict criteria for allowable imprecision updated by 
Westgard and based on biological variation [18], [19], 
the desirable imprecision for FT4 should be 2.9 CV%, a 
value that has not been achieved by FT4 Immulite 2000 
assay manufacturer either, and for certain concentration 
levels, nor by FT4 Maglumi 800 assay manufacturer. 
Similar findings for FT4 Immulite 2000 assay were 
declared by Hendriks et al. [7]. A recent Chinese study 
revealed lower precision rates for several FT4 assays 
compared to precision performance of TSH assays on 
different analytical platforms [20].
The other important issue, while introducing 
a novel immunoassay analyzer, is comparability of 
results obtained by candidate and routine method. 
From the available literature reviewed, immunoassays 
are prone to analytical bias due to majority of factors. 
For this reason, in 2005, International Federation 
of Clinical Chemistry (IFCC) established a Working 
Group on Standardization of Thyroid Function Tests 
(WG-STFT) with an ultimate goal to standardize and 
harmonize TFTs [21]. It was restructured in 2012 to 
Committee for Standardization of Thyroid Function 
Tests (C-STFT) [22]. Regarding TSH immunoassays, 
to obtain comparable test results between methods, 
manufacturers are obliged to recalibrate their methods 
by adjusting the master calibrators to the all-method 
mean values, to harmonize assays [23]. These 
activities were expected to gain less test variability, 
as was confirmed by Faix and Miller [24]. Our results 
from TSH comparison tests revealed good agreement 
between TSH Maglumi 800 and TSH Immulite 2000 test 
results, despite of using different standard calibrators 
(WHO third IRP 81/565 and WHO second IRP 80/558, 
respectively). Mann–Whitney U-test and Paired t-test did 
not show significant differences and 95% CIs included 
0 for intercept and 1 for slope, suggesting acceptable 
method agreement. The average percentage of 
difference was 5.4%, which was below 7.8% as a 
criterion for acceptable bias for serum TSH [16].
For the FT4 immunoassays, IFCC WG-STFT 
and later the C-STFT, proposed standardization against 
reference method based on equilibrium dialysis-
isotope dilution-mass spectrometry [21]. In addition, 
small biological variation of FT4 serum concentration 
demands high performance from the analytical 
method. Recent criteria for acceptable performance 
of FT4 immunoassays are aforementioned 2.9% 
for imprecision and 3.3% for bias. Nonetheless, 
despite of standardization procedures, in routine 
laboratory settings, these criteria are not always 
accomplished [20], [25]. Furthermore, significant bias 
Figure 6: Bland-Altman plots for FT4 measurements: (a) Differences 
between Immulite 2000 and Maglumi 800 measurements expressed 
as absolute units; (b) differences between Immulite 2000 and 
Maglumi 800 measurements expressed as percentage of values)
a
b
 Kuzmanovska  and Miladinova. Comparison of TSH and FT4 Immunoassays
Open Access Maced J Med Sci. 2020 Apr 25; 8(B):168-174. 173
and marked variations between methods have been 
reported [26], with substantial impact of reference range 
intervals. In concordance with, the data from literature 
were our findings from two FT4 method comparison 
studies. Mann–Whitney U-test and paired t-test 
revealed significant differences between FT4 Maglumi 
800 and FT4 Immulite 2000 test results, obtained from 
40 serum samples covering reference range, low and 
high FT4 concentration. The bias of ‒22.8% obtained 
from Bland-Altman Plot suggested poor agreement 
between methods and higher FT4 Maglumi 800 results.
Conclusion
The results of our study signify the importance 
of verification process that should be performed while 
introducing a novel immunoassay method. For TSH, 
we obtained good precision and in comparison study, 
we found close agreement between Maglumi 800 and 
Immulite 2000 methods, which assured transferability 
of results and reporting within the same reference 
interval. However, FT4 assay performance evaluation 
revealed higher imprecision of Maglumi 800 platform 
and significant differences of test results. Thus, clinical 
interpretation of FT4 results is method-dependent and 
requires establishment of new reference range for 
Maglumi 800 analytical platform.
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